ReviewClinical science (London, England : 1979)2023
Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease.
Review in Clinical science (London, England : 1979), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Interactions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Water extract of Artemisia capillaris alleviates fatty liver hemorrhagic syndrome in laying hens by modulating the gut microbiota-bile acid axis.Poultry science · 2026Article
- Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.Pharmacological reviews · 2026Review
- Targeting the intestinal barrier with traditional Chinese medicine for non-alcoholic fatty liver disease: mechanistic insights and therapeutic perspectives.Chinese medicine · 2026Review
- The liver-gut-brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives.Frontiers in endocrinology · 2026Review
- The microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia.Gut microbes · 2025Article
- Towards the clinical use of peripheral bile acids: Recommendations to limit their preanalytical and analytical sources of variability.Practical laboratory medicine · 2025Article
- Impact of Isoquinoline Alkaloids on the Intestinal Barrier in a Colonic Model ofInternational journal of molecular sciences · 2025Article
- Different types of bile acids exhibit opposite regulatory effects on lipid metabolism in finishing pigs through bile acid receptors.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2025Article
- A gut microbiota-independent mechanism shapes the bile acid pool in mice with MASH.JHEP reports : innovation in hepatology · 2024Article
- Metabolic dysfunction associated fatty liver disease in healthy weight individuals.Hepatology international · 2024Review
- Secondary bile acids are associated with body lipid accumulation in obese pigs.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2024Article
- A small intestinal bile acid modulates the gut microbiome to improve host metabolic phenotypes following bariatric surgery.Cell host & microbe · 2024Article
- Importance of the gut microbiota in mice with a 'humanized' bile acid pool.Clinical science (London, England : 1979) · 2024Article
- The impact of 3-sulfo-taurolithocholic acid on ATPase activity in patients' colorectal cancer and normal colon tissues, and its hepatic effects in rodents.Frontiers in veterinary science · 2024Article
- Roles of gut microbes in metabolic-associated fatty liver disease.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bile acids synthesized within the hepatocytes are transformed by gut microorganisms and reabsorbed into the portal circulation. During their enterohepatic cycling, bile acids act as signaling molecules by interacting with receptors to regulate pathways involved in many physiological processes. The bile acid pool, composed of a variety of bile acid species, has been shown to be altered in diseases, hence contributing to disease pathogenesis. Thus, understanding the changes in bile acid pool size and composition in pathological processes will help to elaborate effective pharmacological treatments. Five crucial steps along the enterohepatic cycle shape the bile acid pool size and composition, offering five possible targets for therapeutic intervention. In this review, we provide an insight on the strategies to modulate the bile acid pool, and then we discuss the potential benefits in non-alcoholic fatty liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.